Medical Equipment

Mammalian Cell Banking Market Forecast: How Big Will It Be by 2030?

February 6, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the worker heat stress monitoring wearable market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Mammalian Cell Banking Market expected to reach by 2030?

The mammalian cell banking market has seen rapid expansion in recent years. Its value is forecast to rise from $3.14 billion in 2025 to $3.5 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.3%. In the past, this expansion was driven by developments such as monoclonal antibody development, the increasing growth of vaccine manufacturing, stringent regulatory quality requirements, the broadening of academic research, and the commercialization of biologics.

The mammalian cell banking market is projected to experience substantial expansion in the coming years, reaching a valuation of $5.31 billion by 2030, propelled by a compound annual growth rate (CAGR) of 11.0%. This anticipated growth during the forecast period is primarily driven by developments in gene therapy, the expansion of personalized medicine, progress in biosimilar development, the robust pipelines of cell-based therapies, and the necessity for long-term cell traceability. Key trends emerging in the forecast period encompass the standardization of cell line preservation techniques, an increase in biopharmaceutical pipelines, the expansion of CGMP-compliant cell banks, a heightened emphasis on genetic stability, and a growing trend of outsourcing to specialized facilities.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28262&type=smp

What Drivers Are Driving Adoption Within The Mammalian Cell Banking Market?

The mammalian cell banking market is anticipated to experience growth driven by the increasing demand for cell-based therapies. These therapies represent advanced medical treatments that utilize living cells, often modified or engineered, to repair, replace, or regenerate damaged tissues and organs, thereby offering targeted solutions for a broad spectrum of diseases. The surge in demand for cell-based therapies stems from the rising prevalence of chronic and rare diseases, which creates an urgent need for more effective and precise treatment options. Mammalian cell banking plays a crucial role in supporting cell-based therapies by offering a reliable, standardized supply of high-quality cells, which ensures consistency, safety, and scalability throughout the development and manufacturing processes of regenerative treatments. For instance, data from April 2024, as reported by the American Society of Gene and Cell Therapy, a US-based non-profit medical and scientific organization, showed that the number of therapies across all clinical pipeline phases has increased since the end of 2023, with Phase I demonstrating the most significant rise of 11% since before the fourth quarter of 2022. Thus, the escalating demand for cell-based therapies is a primary catalyst for the expansion of the mammalian cell banking market.

What Segments Are Included Within The Mammalian Cell Banking Market?

The mammalian cell banking market covered in this report is segmented –

1) By Product Type: Master Cell Bank, Working Cell Bank

2) By Cell Type: Chinese Hamster Ovary Mammalian Cell Banking (CHO), Baby Hamster Kidney (BHK), Non-Secreting 0 (NS0), YB2/0 And P2/0, Human Embryonic Kidney 293 (HEK293) And Derivatives, Henrietta Lacks (HELA)

3) By Storage Type: Liquid Nitrogen, Controlled Rate Freezer, Flash Freezing

4) By Application: Drug Development, Vaccine Production, Gene Therapy, Monoclonal Antibody Production

5) By End User: Academic And Research Laboratories, Biopharmaceutical Companies, Contract Research Organizations (CROs)

Subsegments:

1) By Master Cell Bank: Recombinant Cell Lines, Hybridoma Cell Lines, Primary Cell Lines, Genetically Engineered Cell Lines, Viral Vector Producing Cell Lines

2) By Working Cell Bank: Current Good Manufacturing Practice (CGMP)-Compliant Cell Banks, Research-Grade Cell Banks, Clinical Trial Cell Banks, Commercial Production Cell Banks, Stability Testing Cell Banks

Which Market Trends Are Opening Growth Opportunities In The Mammalian Cell Banking Market?

Leading companies in the mammalian cell banking market are concentrating on developing advanced solutions, such as innovative stable cell line systems, to boost cell line productivity, maintain long-term genetic consistency, and streamline biopharmaceutical manufacturing processes. Stable cell line systems are genetically engineered mammalian cells designed for the continuous production of a desired protein or therapeutic molecule over multiple generations, exhibiting high genetic stability and reproducibility. For instance, in August 2024, WuXi Biologics, a China-based biopharmaceutical company, launched the WuXia293 Stable platform, an innovative HEK293-based stable cell line system specifically engineered for the development and manufacturing of difficult-to-express biologic molecules. Utilizing proprietary mammalian cell line development technology, this platform ensures stable expression and consistent quality throughout long-term cell passages. The WuXia293 Stable platform addresses challenges such as low yields and compromised quality frequently observed with traditional CHO cell systems by providing high protein titers, improved human-like glycosylation, and scalable production suitable for clinical and commercial manufacturing.

Who Are The Prominent Global Companies Shaping The Mammalian Cell Banking Market Landscape?

Major companies operating in the mammalian cell banking market are Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, Eurofins Scientific SE, Charles River Laboratories International Inc., Catalent Inc., Sartorius Stedim Biotech S A, Samsung Biologics Co Ltd, CMIC Holdings Co Ltd, WuXi Biologics Inc., Evotec SE, AGC Biologics Inc., GenScript ProBio Co Ltd, Syngene International Limited, KBI Biopharma Inc., Rentschler Biopharma SE, Polpharma Biologics S A, Abzena plc, 53Biologics, Cellistic, GBI Biomanufacturing, ABL Inc, OmniaBio, uBriGene Biosciences

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/mammalian-cell-banking-global-market-report

Which Region Is Projected To Lead The Mammalian Cell Banking Market During The Forecast Period?

North America was the largest region in the mammalian cell banking market in 2025. The regions covered in the mammalian cell banking market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Mammalian Cell Banking Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28262&type=smp

Browse Through More Reports Similar to the Global Mammalian Cell Banking Market 2026, By The Business Research Company

Cell Cultures Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-cultures-global-market-report

Cell Harvesting Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-harvesting-global-market-report

Cell Based Assays Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795